Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Seagen Inc.
Incyte Corporation
French Innovative Leukemia Organisation
University of Cologne
Seagen Inc.
Stanford University
National Cancer Institute (NCI)